Dompet Molecules of Korolchuk IP-NFT yang aman & terlindungi
Kendalikan Molecules of Korolchuk IP-NFT aset Anda sepenuhnya dengan percaya diri di ekosistem Trezor.
- Diamankan oleh dompet perangkat keras Anda
- Gunakan dengan dompet panas yang kompatibel
- Dipercaya oleh lebih dari 2 juta pelanggan

Kirim & terima Molecules of Korolchuk IP-NFT Anda dengan aplikasi Trezor Suite
Kirim & terima
Dompet perangkat keras Trezor yang mendukung Molecules of Korolchuk IP-NFT
Sinkronkan Trezor Anda dengan aplikasi dompet
Jaringan Molecules of Korolchuk IP-NFT yang didukung
Mengapa dompet perangkat keras?
Offline bersama Trezor
- Anda memiliki 100% koin Anda
- Dompet Anda 100% aman secara offline
- Data Anda 100% anonim
- Koin Anda tidak terikat pada perusahaan mana pun
Bursa online
- Jika sebuah bursa gagal, Anda akan kehilangan koin Anda
- Bursa menjadi target para peretas
- Data pribadi Anda mungkin terekspos
- Anda tidak benar-benar memiliki koin Anda
Cara menggunakan VITA-FAST di Trezor
Hubungkan Trezor Anda
Buka aplikasi dompet pihak ketiga
Kelola aset Anda
Maksimalkan VITA-FAST Anda
Trezor menjaga VITA-FAST Anda tetap aman
Dilindungi oleh Secure ElementPerlindungan terbaik terhadap ancaman online dan offline
Token Anda, kendali AndaKontrol penuh atas setiap transaksi dengan konfirmasi langsung di perangkat
Keamanan dimulai dengan open-sourceDesain dompet transparan membuat Trezor Anda lebih baik dan lebih aman
Cadangan dompet yang jelas & sederhanaPulihkan akses ke aset digital Anda dengan standar cadangan baru
Percaya diri sejak hari pertamaSegel pengaman kemasan & perangkat melindungi integritas Trezor Anda
What is the project about?
VitaDAO, a decentralized autonomous organization, introduces VITA-FAST, an innovative funding model for longevity research. Leveraging the Ethereum blockchain, VITA-FAST are ERC-20 tokens, signifying fractional ownership of the Intellectual Property Non-Fungible Token (IP-NFT) from longevity research conducted at the Korolchuk Lab, Newcastle University. VITA-FAST token holders gain governance rights over the IP, democratizing the decision-making processes in scientific research.
- What is the project about?
The project is focused on discovering and developing therapeutic compounds that can reactivate autophagy in Npc1 -/- cells. This involves screening bioactive and commercial small molecules in cell survival assays to identify potential autophagy activators that are not cytotoxic. The project uses advanced techniques like luciferase-p6 clearance and Halo-GFP-LC3 orthogonal assays for this purpose.
- What makes your project unique?
The project's uniqueness lies in its approach to identifying novel compounds that can induce autophagy in NPC1 -/- cells, a crucial process for treating Niemann-Pick Type C disease. Unlike existing treatments, this project employs high-throughput screening methods and innovative assays to discover compounds with high chemical variability and no similarity to existing autophagy inducers, opening up possibilities for new iIP.
- History of your project.
The project, led by Dr. Korolchuk and his team at Newcastle University, has progressed from generating data on thousands of compounds using advanced screening assays to identifying lead compounds with potential autophagic properties. It has evolved to include the synthesis of derivatives of these compounds and is now moving towards drug translation processes, including pharmacokinetics and scalability studies.
- What’s next for your project?
The next steps involve screening third-generation compounds, conducting in vitro and in vivo models using patient